Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States: Review of the First 3 Years of Postlicensure Data

  title={Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States: Review of the First 3 Years of Postlicensure Data},
  author={Jacqueline e. Tate and Margaret M Cortese and Daniel C. Payne and Aaron T. Curns and Catherine Yen and Douglas H. Esposito and Jennifer E. Cortes and Benjamin A. Lopman and Manish M Patel and Jon R. Gentsch and Umesh D. Parashar},
  journal={The Pediatric Infectious Disease Journal},
Background: Rotavirus vaccine was recommended for routine use in US infants in 2006. Before the introduction of vaccine, rotavirus was the most common cause of severe gastroenteritis in children <5 years of age in the United States. Methods: We reviewed published data to summarize the US experience during the first 3 years of its rotavirus vaccination program. Results: Rotavirus seasons have been delayed and diminished in magnitude during the postvaccine era compared with the prevaccine era… 
A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact
The increasing use ofRotavirus vaccines has substantially diminished the burden and changed the epidemiology of rotavirus disease in U.S. children; efforts to increase rotav virus vaccine coverage should continue.
Lessons from the US rotavirus vaccination program.
An unanticipated finding was that hospital admissions for diarrhea also declined among unvaccinated individuals aged 5 through 24 years, suggesting that the vaccine was having a herd effect, perhaps by preventing rotavirus transmission from a younger immunized cohort.
Effects of vaccine on rotavirus disease in the pediatric population
  • P. Dennehy
  • Medicine
    Current opinion in pediatrics
  • 2012
Two well tolerated and effective rotav virus vaccines have reduced the health burden of rotavirus gastroenteritis in both developed and developing countries.
Effectiveness and impact of rotavirus vaccines in the United States – 2006–2012
Substantial decreases in severe diarrheal disease in US children, exceeding the level expected based on vaccine coverage, as well as the extension of benefits to older age groups ineligible for vaccination have demonstrated both the direct and indirect impacts of vaccination in the USA.
Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009.
  • D. Payne, M. Staat, U. Parashar
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
Rotavirus vaccination has dramatically decreased rates of hospitalization for rotavirus infection among children in these US counties in 2008 and although rates among age groups eligible for vaccination remained low in 2009, indirect benefits disappeared.
Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea
Implementation of rotavirus vaccines has substantially decreased hospitalizations from rotav virus and all-cause AGE during the first 10 years since vaccine licensure, including recent evidence from countries with high child mortality.
Assessing the impacts of the first year of rotavirus vaccination in the United Kingdom.
In the first year after the introduction of universal vaccination against rotavirus, a profound reduction in gastroenteritis presentations and admissions was observed with a substantial possible herd effect seen in older children.
Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010.
It is demonstrated how direct, indirect, total, and overall effectiveness estimates and absolute benefits of rotavirus vaccines vary through the years following vaccine introduction, and how this could underestimate the sustained impact of the vaccine program.


Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States
Routine rotavirus vaccination would unlikely be cost-saving in the United States at present, but may still be considered a cost-effective intervention.
Projected Impact of the new rotavirus vaccination program on hospitalizations for gastroenteritis and rotavirus disease among US children <5 years of age during 2006-2015.
Vaccination is expected to substantially reduce the health burden of hospitalizations for rotavirus disease among US children during 2006-2015, and the impact of vaccination based on direct protective effects alone was expected to first occur for hospitalization for AGE among infants during winter 2009.
Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003.
The largest US hospital discharge database available, the Healthcare Cost and Utilization Project (HCUP), is used to study national rates, trends, and risk factors for diarrhea- and rotavirus-associated hospitalizations and deaths among children <5 years of age, to establish a baseline against which vaccine implementation can be measured.
Implementation of Rotavirus Immunization in Philadelphia, Pennsylvania: High Levels of Vaccine Ineligibility and Off-Label Use
In the first 6 months of availability, pentavalent rotavirus vaccine frequently was used off-label for age, underscoring the importance of education of immunization providers.
Diarrhea- and Rotavirus-Associated Hospitalizations Among Children Less Than 5 Years of Age: United States, 1997 and 2000
An effective rotavirus vaccine will likely reduce substantially the burden of severe rotav virus disease, estimated to account for 4% to 5% of all hospitalizations and ∼30% of hospitalizations for watery diarrhea among children <5 years of age.
Rotavirus vaccination coverage among infants aged 5 months - immunization information system sentinel sites, United States, June 2006-June 2009.
Analysis of data from Immunization Information System sentinel sites found that RV coverage among infants aged 5 months was 13% lower than the average coverage with >or=1 dose DTaP and PCV7 at these same sites, which could reflect typical new-vaccine coverage dynamics, the presence of RV-specific barriers, or both.
Effectiveness of the Pentavalent Rotavirus Vaccine in Preventing Gastroenteritis in the United States
In this first nationwide study evaluating VE under conditions of routine use, RV5 was highly effective in preventing RGE and AGE and in reducing health care resource utilization.
Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states.
The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
Active, Population-Based Surveillance for Severe Rotavirus Gastroenteritis in Children in the United States
OBJECTIVES. Routine vaccination of US infants against rotavirus was implemented in 2006, prompting the Centers for Disease Control and Prevention New Vaccine Surveillance Network to begin